SPY441.40-4.34 -0.97%
DIA345.64-1.80 -0.52%
IXIC15,043.97-137.96 -0.91%

BRIEF-Sequana Medical H1 Net Loss Deepens To EUR 11.9 Mln

reuters.com · 09/02/2021 01:08
BRIEF-Sequana Medical H1 Net Loss Deepens To EUR 11.9 Mln

- SEQUANA MEDICAL NV SEQUA.BR:

  • ANNOUNCES H1 2021 RESULTS AND PROVIDES BUSINESS UPDATE

  • TOTAL LIQUIDITY POSITION OF EUR 21.8 MILLION PROVIDES CASH RUNWAY INTO Q2 2022

  • ALFAPUMP® - POSITIVE RESULTS FROM SECOND INTERIM ANALYSIS OF POSEIDON PIVOTAL STUDY; AWAITING FDA APPROVAL ON POSEIDON PIVOTAL STUDY EXPANSION

  • ALFAPUMP® - FDA REGULATORY SUBMISSION NOW EXPECTED IN MID-2023 DUE TO WORLDWIDE SUPPLY SHORTAGE OF ELECTRONIC COMPONENTS; EUROPEAN COMMERCIAL ACTIVITIES AND CLINICAL STUDIES UNAFFECTED

  • ASSUMING NO FURTHER COVID-19 RELATED RESTRICTIONS, COMPANY EXPECTS TO GENERATE 2021 REVENUES, ON A PRO RATA BASIS, IN LINE WITH PERIODS BEFORE REDUCED MANUFACTURING SUPPLY

  • H1 NET LOSS EUR 11.9 MILLION VERSUS LOSS OF EUR 9.6 MILLION YEAR AGO

  • H1 EBIT LOSS OF EUR 11.5 MILLION VERSUS LOSS OF EUR 8.9 MILLION YEAR AGO

  • H1 REVENUE EUR 23,000 VERSUS EUR 0.6 MILLION YEAR AGO

  • CONTINUES TO MONITOR IMPACT OF COVID-19 ON ITS ACTIVITIES, PARTICULARLY IN RESPECT TO POSEIDON AND ITS EUROPEAN COMMERCIAL BUSINESS

Source text for Eikon: ID:nGNX8lDWSM

Further company coverage: SEQUA.BR


(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))